(Q38558730)

4 September 2017

1 reference

title

Development of an AIDS vaccine using Sendai virus vectors (English)

1 reference

4 September 2017

0 references

0 references

Hiroshi Ishii

1

1 reference

4 September 2017

Tetsuro Matano

series ordinal

2

1 reference

4 September 2017

language of work or name

English

0 references

publication date

28 July 2015

1 reference

4 September 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

4 September 2017

volume

33

1 reference

4 September 2017

issue

45

1 reference

4 September 2017

page(s)

6061-6065

1 reference

Towards an HIV-1 cure: measuring the latent reservoir

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

CD8(+) T cells in preventing HIV infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

A Blueprint for HIV Vaccine Discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Neutralizing antibodies to HIV-1 induced by immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

The influence of delivery vectors on HIV vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Primary replication of a recombinant Sendai virus vector in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Impact of MHC class I diversity on immune control of immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in burmese rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Immunodominance: a pivotal principle in host response to viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

HIV and SIV CTL escape: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Design and pre-clinical evaluation of a universal HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Definition of the viral targets of protective HIV-1-specific T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Expanding roles for CD4⁺ T cells in immunity to viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Harnessing CD4⁺ T cell responses in HIV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

HIV preferentially infects HIV-specific CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Cutting edge: MHC class II-restricted killing in vivo during viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

Cytolytic CD4(+) T cells in viral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.114

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.06.114

1 reference

4 September 2017

1 reference